{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:26:35Z","timestamp":1744259195110,"version":"3.40.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,9]]},"DOI":"10.7759\/cureus.81973","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:49:56Z","timestamp":1744238996000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable Response to Pembrolizumab With Chemotherapy in EGFR-Mutated Squamous Cell Lung Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Taira","family":"Ninomaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mukaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiko","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2011.1182","article-title":"Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma","volume":"25","author":"Miyamae Y","year":"2011","unstructured":"Miyamae Y, Shimizu K, Hirato J, et al.. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 2011, 25:921-8. 10.3892\/or.2011.1182","journal-title":"Oncol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17915","article-title":"Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: a multicenter study and pooled analysis of published reports","volume":"8","author":"Liu Y","year":"2017","unstructured":"Liu Y, Zhang Y, Zhang L, et al.. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: a multicenter study and pooled analysis of published reports. Oncotarget. 2017, 8:49680-8. 10.18632\/oncotarget.17915","journal-title":"Oncotarget"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2013.09.15","article-title":"Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation","volume":"5","author":"Fang W","year":"2013","unstructured":"Fang W, Zhang J, Liang W, et al.. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis. 2013, 5:585-92. 10.3978\/j.issn.2072-1439.2013.09.15","journal-title":"J Thorac Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi S","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, et al.. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005, 352:786-92. 10.1056\/NEJMoa044238","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.012","article-title":"Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations","volume":"13","author":"Toki MI","year":"2018","unstructured":"Toki MI, Mani N, Smithy JW, et al.. Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations. J Thorac Oncol. 2018, 13:1884-96. 10.1016\/j.jtho.2018.09.012","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami N","year":"2022","unstructured":"Nogami N, Barlesi F, Socinski MA, et al.. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022, 17:309-23. 10.1016\/j.jtho.2021.09.014","journal-title":"J Thorac Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000098","article-title":"How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?","volume":"9","author":"Hata A","year":"2014","unstructured":"Hata A, Katakami N, Yoshioka H. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?. J Thorac Oncol. 2014, 9:e20. 10.1097\/JTO.0000000000000098","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng MW","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015, 75:2139-45. 10.1158\/0008-5472.CAN-15-0255","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi NA","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, et al.. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015, 348:124-8. 10.1126\/science.aaa1348","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong ZY","year":"2017","unstructured":"Dong ZY, Zhang JT, Liu SY, et al.. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology. 2017, 6:e1356145. 10.1080\/2162402X.2017.1356145","journal-title":"Oncoimmunology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3991","article-title":"Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer","volume":"81","author":"Wang X","year":"2021","unstructured":"Wang X, Ricciuti B, Nguyen T, et al.. Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. Cancer Res. 2021, 81:2566-73. 10.1158\/0008-5472.CAN-20-3991","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680804","article-title":"EGFR-mutated squamous cell lung cancer and its association with outcomes","volume":"11","author":"Jin R","year":"2021","unstructured":"Jin R, Peng L, Shou J, et al.. EGFR-mutated squamous cell lung cancer and its association with outcomes. Front Oncol. 2021, 11:680804. 10.3389\/fonc.2021.680804","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin M","year":"2019","unstructured":"Offin M, Rizvi H, Tenet M, et al.. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res. 2019, 25:1063-9. 10.1158\/1078-0432.CCR-18-1102","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356949-durable-response-to-pembrolizumab-with-chemotherapy-in-egfr-mutated-squamous-cell-lung-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:49:58Z","timestamp":1744238998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356949-durable-response-to-pembrolizumab-with-chemotherapy-in-egfr-mutated-squamous-cell-lung-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.81973","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}